Thursday, 18 Jul 2019

You are here

Dietary Supplements Fail to Reduce Mortality Risks

An NIH funded prospective study has shown that the use of daily dietary supplements was not associated with a subsequent lowering of mortality risk.

Data from 30,899 adults surveyed in NHANES (National Health and Nutrition Examination Survey) sought to examine the association between dietary supplement use, levels of nutrient intake from foods and supplements, and mortality. Outcomes included mortality from all causes, cardiovascular disease (CVD), and cancer.

A total of 3613 deaths occurred with 6.1 years of follow-up; including 945 CVD deaths and 805 cancer deaths.

Ever-use of dietary supplements was not associated with mortality outcomes.

Adequate intake of vitamin A, vitamin K, magnesium, zinc, and copper was associated with reduced all-cause or CVD mortality, but the associations were restricted to nutrient intake from foods, rather than supplements.

Excess intake of calcium (especially from supplements) was associated with increased risk for cancer death (adjusted rate ratio, 1.62 [95% CI, 1.07 to 2.45]).  When comparing ≥1000 mg/d vs. no use, supplement calcium intake was associated with a 503% increase risk of cancer (adjusted rate ratio, 1.53 [CI, 1.04 to 2.25]).

Overall the authors concluded that the use of dietary supplements is not associated with mortality benefits among U.S. adults.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rituximab Superior to Cyclosporine for Membranous Nephropathy

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

FDA Public Review of CBD Oil

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

In his opening remarks, the FDA acting Commissioner Dr. Ned Sharpless said, "critical questions remain about the safety" of CBD products, especially since the growth of the CBD market has exploded in the past year.

Steroids, Not Biologics, Drive Arthroplasty Infections in RA

Medicare and Truven MarketScan administrative data study (2006 through 2015) of rheumatoid arthritis (RA) undergoing arthroplasty found that while that the risks of perioperative infection was similar across biologics, the infection risk with glucocorticoid use, especially at > 10 mg/d, was significantly greater.